Ethic Inc. increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 18.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 67,733 shares of the company’s stock after buying an additional 10,438 shares during the period. Ethic Inc.’s holdings in Takeda Pharmaceutical were worth $1,140,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Concord Wealth Partners boosted its holdings in Takeda Pharmaceutical by 61.7% during the first quarter. Concord Wealth Partners now owns 1,712 shares of the company’s stock worth $31,000 after buying an additional 653 shares in the last quarter. SRS Capital Advisors Inc. purchased a new position in Takeda Pharmaceutical during the second quarter valued at $40,000. Huntington National Bank lifted its holdings in Takeda Pharmaceutical by 30.2% during the second quarter. Huntington National Bank now owns 3,276 shares of the company’s stock valued at $55,000 after purchasing an additional 759 shares in the last quarter. Bessemer Group Inc. purchased a new position in Takeda Pharmaceutical during the first quarter valued at $62,000. Finally, Captrust Financial Advisors lifted its holdings in Takeda Pharmaceutical by 32.4% during the first quarter. Captrust Financial Advisors now owns 8,107 shares of the company’s stock valued at $148,000 after purchasing an additional 1,985 shares in the last quarter. 2.99% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE TAK opened at $16.75 on Wednesday. The firm has a 50-day simple moving average of $16.76 and a 200-day simple moving average of $17.19. The stock has a market capitalization of $53.01 billion, a price-to-earnings ratio of 11.47 and a beta of 1.05. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 0.83. Takeda Pharmaceutical Company Limited has a 52 week low of $15.30 and a 52 week high of $19.97.
Separately, Zacks Investment Research downgraded shares of Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Wednesday.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Co, Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products.
Recommended Story: What is a Market Correction?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.